Oppenheimer Asset Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Oppenheimer Asset Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,644	Closed	-$1.11M	–	1188
2022 Q2	$1.11M	Sell	7,644 -309	-4%	-$39.5K	0.02%	643
2022 Q1	$943K	Sell	7,953 -20	-0.3%	-$2.49K	0.01%	757
2021 Q4	$1.1M	Buy	7,973 +5,741	+257%	+$730K	0.01%	752
2021 Q3	$310K	Sell	2,232 -66	-3%	-$8.24K	﹤0.01%	1049
2021 Q2	$223K	Buy	+2,298	New	+$187K	﹤0.01%	1124
2021 Q1	–	Sell	-2,531	Closed	-$217K	–	1233
2020 Q4	$217K	Buy	+2,531	New	+$214K	﹤0.01%	1060
2020 Q2	–	Sell	-2,681	Closed	-$91K	–	1538
2020 Q1	$91K	Sell	2,681 -144	-5%	-$6.58K	﹤0.01%	1126
2019 Q4	$154K	Sell	2,825 -19	-0.7%	-$941	﹤0.01%	1111
2019 Q3	$119K	Buy	+2,844	New	+$120K	﹤0.01%	1146

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Oppenheimer Asset Management's BHVN Position: Q3 2022 in Review

Oppenheimer Asset Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q3 2022, closing a stake of 7,644 shares — an estimated $1.11M sold.

Oppenheimer Asset Management first reported a position in BHVN in Q3 2019 and held it in 9 quarters. The position peaked at $1.11M in Q2 2022. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Oppenheimer Asset Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q3 2022 after selling out during the quarter.
Oppenheimer Asset Management sold 7,644 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $1.11M.
Oppenheimer Asset Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2019 and held it in 9 quarters.
Oppenheimer Asset Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $1.11M in Q2 2022.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Oppenheimer Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.